eng 130920 n h1 4 pdf用 - daiichisankyo.com · companies play an integral part in medical...
TRANSCRIPT
www.daiichisankyo.com
Corporate Brochure
■H04-01■H04-01
Corporate PhilosophyG l o b a l advances i n med ica l t echnolog y a n d
pharmaceuticals have saved the l ives of a great
many people and contributed to healthier lifestyles.
However, there are st i l l many diseases for which
the level of satisfaction with treatment is insufficient
or for which there is no established t reatment .
Preventative measures, treatments and therapies
that can be ta i lored to each pat ient ’s part icular
condition are also in great demand. Pharmaceutical
companies play an integral part in medical treatment and
are depended upon to provide solutions to these problems.
Daiichi Sankyo’s commitment to providing what people
really need is summed up in our corporate mission: “ To
contribute to the enrichment of quality of life around the
world through the creation of innovative pharmaceuticals,
and through the provision of pharmaceuticals addressing
diverse medical needs.” In order to fulfill this mission,
the Daiichi Sankyo Group has devoted itself with a
strong sense of duty to doing all that it can to meet
society’s expectations.
At Daiichi Sankyo, our vision is to become a Global Pharma
Innovator that can meet diverse medical needs around the
world—a company that is capable of sustainable growth. In
keeping with this vision, we have proactively implemented a
range of initiatives, focusing on expanding the Group’s global
business reach, fulf illing unmet medical needs and building
innovative products and business models.
Vision
Joji NakayamaRepresentative Director,
President and CEO
Daiichi Sankyo’s mission is to contr ibute to t he
enrichment of the qual ity of l i fe around the world
through the creation of innovative pharmaceuticals
and through the provision of pharmaceuticals that
address diverse medical needs.
The business environment facing the pharmaceutical
industry continues to evolve in Japan and around
the world. In the midst of these changing conditions,
we are working to realize our vision of becoming a
Global Pharma Innovator. To that end, we are striving
to satisfy unmet medical needs as a developer of new
drugs, including vaccines, generic and OTC drugs, that
meet a variety of medical needs.
As a leader in the healthcare industry, we recognize
that we have multiple responsibili t ies to our many
stakeholders. We not only have a responsibilit y to
provide the pharmaceuticals that are indispensable
today to healthcare systems around the world, but we
must also fund the research and development that
ensures the avai labi l i ty of tomorrow’s innovative
medicines. We also have a responsibility to support the
communities in which we live and work. We commit to
achieving these important goals while delivering earnings
growth to our shareholders and doing our utmost to earn
the trust of all our stakeholders. By embracing these
responsibilities, we hope to be a company worthy of
representing Japan as a cutting-edge global enterprise.
Thank you for your continued support.
Message from the CEO
Ou
r Messag
eB
usiness S
trategyR
&D
Marketing
CS
RH
istory
Regio
nal Activities
Ou
r Messag
eB
usiness S
trategyR
&D
Marketing
CS
RH
istory
Regio
nal Activities
■P01-02
In addition to its home market of Japan, Daiichi Sankyo’s
products are marketed in the United States and in many
countries in Europe and Asia. This global reach, and the
important insights it provides, is essential to our ability to
serve the diverse needs of patients and healthcare
professionals around the world. Through the creation and
supply of new drugs, Daiichi Sankyo’s contribution to
the health of people worldwide knows no borders, and to
foster this global perspective, we promote cross-company
information exchanges among such departments as
Research & Development, Supply Chain, and Marketing.
Daiichi Sankyo has developed our unique business model
to address market and customer diversity and optimize
growth opportunities across the value chain — from drug
discovery to marketed products and suppor t services
available to patients around the world. This business model
combines our strength in developing and marketing
innovative ( patent-protected ) products with the generic
drug capabili ties of Ranbaxy Laboratories Ltd., a
Daiichi Sankyo Group company. As one of the world’s top
generic manufacturers, Ranbaxy not only has a strong
presence in India, but also in developing countries around
the world. This enables us to extend our global reach to
fulfill the medical needs of both industrialized countries and
emerging markets, while maximizing opportunities with a
broad product portfolio.
Global Business Activities
Our Business
Innovative pharmaceuticals continues to be the Group’s core
business area. We supply high-quality pharmaceuticals
that meet unmet medical needs, as well as the timely,
accurate, and easy-to-understand information that patients
and their physicians deserve.
Business Activities in JapanInnovative pharmaceuticals
Besides the research and early development and marketing
of vaccines carried out on its own, Daiichi Sankyo also
maintains strategic ties with two joint ventures: Kitasato
Daiichi Sankyo Vaccine Co., Ltd. (a joint venture with Kitasato
Institute), whose strength lies in production and chemistry,
manufacturing and controls (CMC), and Japan Vaccine Co.,
Ltd. (a joint venture with GlaxoSmithKline), which specializes
in the latter phase of vaccine development and sales.
These alliances enable us to create a seamless value chain,
from discovery to the delivery of products, ensuring a
stable supply of the vaccines the public needs.
Vaccines
The concept of “self-medication” has become increasingly
common and customer needs have consequently become
increasingly diverse. It is with this background in mind that
the Daiichi Sankyo Group has established its consumer
healthcare business, which includes OTC pharmaceuticals,
functional skincare products, and food products, as one of
its core businesses. Daiichi Sankyo Healthcare Co., Ltd., a
Daiichi Sankyo Group company, is working to fur ther
develop the Group’s self-medication business.
OTC pharmaceuticals
Building on the trust and confidence that Daiichi Sankyo has
cultivated as a developer and manufacturer of innovative
drugs, Daiichi Sankyo Espha Co., Ltd. works to create the
added value that will allow it to supply quality generic
pharmaceuticals as well. Particularly in the area of product
safety, the Company manufactures products in dosage
forms and with labels designed for ease and accuracy of
use. These effor ts include, for example, inscribing the
name of the drug on both sides of tablets. Moreover,
Daiichi Sankyo has launched a series of premium generic
products that build upon the brand’s expertise and add
new value. We hope these products will help Daiichi Sankyo
reinforce its brand differentiation and capture a larger share
of the market.
Generic pharmaceuticals
Ou
r Messag
eB
usiness S
trategyR
&D
Marketing
CS
RH
istory
Regio
nal Activities
■P03-04
GEMRADDaiichi Sankyo established the Global Executive Meeting
of Research and Development (GEMRAD) as our top
decision-making body for global R&D. GEMRAD makes
management-level “go/no-go” decisions on development
projects and manages global R&D activities across functions
and regions. Its members represent various divisions,
including those responsible for R&D, global sales, licensing,
pharmaceutical affairs, and product portfolios.This enables
GEMRAD to make appropriate decisions based on
comprehensive assessments covering everything from
research to marketing.
Research and DevelopmentA global R&D network that connects operations in Japan and throughout the worldOur worldwide research and development (R&D) network
connects Japan, the United States, Europe, India and East
Asian countries. This multinational approach allows us to
leverage expertise from around the world to execute clinical
trials and strengthen our global decision-making. Our R&D
operations, as well as those of Daiichi Sankyo RD Novare
and Asubio Pharma, are primarily based at four sites near
Tokyo, and they collaborate with Daiichi Sankyo, Inc. in the
United States and Daiichi Sankyo GmbH in Europe on
everything from drug discovery to development and
manufacturing. In the United States, Daiichi Sankyo Pharma
Development oversees global clinical trials from its
headquarters in Edison, New Jersey, while Daiichi Sankyo
Development in the UK oversees clinical trials from its
headquarters in Gerrards Cross, Buckinghamshire. In India,
we have acquired Ranbaxy's new drug development
facili ties, which we renamed the Daiichi Sankyo Life
Science Research Centre in India ( RCI ), to fur ther
strengthen our research network. As a par t of our
Global Development hub in Asia, Daiichi Sankyo Korea,
Daiichi Sankyo Taiwan, and Daiichi Sankyo ( China )
Holdings are contributing to the ongoing launch of new
products. In Europe, U3 Pharma and the Tissue & Cell
Research Center Munich ( TCRM ) are located in the
suburbs of Munich and carry out antibody pharmaceutical
research and ADME/ Tox studies. In the U.S., Plexxikon Inc.
in Berkeley, California is the newest R&D affiliate and
was acquired in March 2011.
Research
❶❷❸
❹❺
❻❼
❶Daiichi Sankyo Co., Ltd.
-Shinagawa R&D Center, Tokyo
-Kasai R&D Center, Tokyo
-Tatebayashi Biopharmaceuticals Center, Gunma
-Hiratsuka (CMC), Kanagawa
❶Daiichi Sankyo RD Novare Co., Ltd.
❶Asubio Pharma Co., Ltd.
❷Daiichi Sankyo ( China) Holdings Co., Ltd.
❸Daiichi Sankyo India Pharma Private Limited
- Daiichi Sankyo Life Science Research Centre in India
- Daiichi Sankyo India Development
❹Daiichi Sankyo Europe GmbH
❹U3 Pharma GmbH
❺Daiichi Sankyo Development Ltd.
❻Daiichi Sankyo, Inc.
❻Daiichi Sankyo Pharma Development
❼Plexxikon Inc.
Ou
r Messag
eB
usiness S
trategyR
&D
Marketing
CS
RH
istory
Regio
nal Activities
■P05-06
Fast and sustained new drug development through systematic researchThrough research and development, we’re working to
create a competitive pipeline and deliver innovative
products quickly and consistently. This supports our vision
of becoming a Global Pharma Innovator. While maintaining
our portfolio of marketed pharmaceuticals for hypertension,
hyperlipidemia, and bacterial infections, we’re developing
treatments for thrombotic disorders — which occur when
clots form in blood vessels. To reinforce the competitiveness
of research in disease areas with high unmet medical
needs, we are also focused on discovering and developing
novel oncology and cardiovascular-metabolic therapies and
substances with novel mechanisms of action.
As patients and healthcare professionals eagerly await new
pharmaceutical solutions, we are expanding our R&D
pipeline through strategic alliances. In 2008, for example,
we acquired Germany-based U3 Pharma AG ( Now U3
Phama GmbH ) , a company with many promising antibody
drug candidates for treating cancer. In 2010, we restructured
our subsidiary Asubio Pharma Co., Ltd. as a drug discovery
venture business. That same year,
Ranbaxy Laboratories transferred its drug discovery
research unit to Daiichi Sankyo India Pharma. We
subsequently established the Daiichi Sankyo Life Science
Research Centre, India (RCI), strengthening our global R&D
structure. Additionally, in 2011, we acquired Plexxikon Inc., a
privately held pharmaceutical company based in Berkeley,
California, with a promising pipeline and technology platform.
Research Early-stage Development Late-stage Development Life Cycle Management and Markets
Discovery Priority Areas : ■Oncology ■Cardiovascular-metabolism
■Thrombotic Disorders
■Hypertension ■Bacterial Infections
■Hyperlipidemia
2007-2009(First MTP*)
Thrombotic disorders,
oncology, diabetes,
autoimmune diseases
and rheumatoid arthritis
Targets From 2010 (Post Second MTP)
*Mid-term Plan
Reinforce competitiveness towards 2015
Pursue new challenges beyond traditional illness areas in preparing for 2015 and beyond
Priority Areas: ■Oncology ■Cardiovascular-metabolism
New Areas: ■Newly address unmet needs
New Areas : ■Drug creation based on disease mechanisms, developing products with a new mechanism of action that address heavily unmet needs.
Expanding our R&D pipeline and improving our research platform
We recognize that we must earn the trust and confidence of
our customers every day, not only through the efficacy
and safety of our products, but through the quality of their
manufacture as well. Our attention to quality begins with the
import of raw materials and continues through production
and distribution. Along that supply chain, we adhere to the
most stringent corporate and regulatory standards,
including internationally recognized standards set by Good
Manufacturing Practice (GMP) and Good Quality Practice
(GQP).
Dedication to quality
Pharmaceutical companies have a mission to reliably and
consistently supply high-quality drugs. Daiichi Sankyo is
fulfilling this role by integrating its operations to consistently
procure raw materials and systematically manufacture
drugs, as well as by using its logistics function to rapidly and
reliably distribute products. This integration facilitates the
centralized management of information, enabling a flexible
and efficient manufacturing and supply system ( supply
chain management ).
Daiichi Sankyo has also established a stable supply system
for the global market by seamlessly linking its production
bases inside and outside of Japan. Consistently supplying
highly reliable products that reproduce the quality of the
drug as designed requires a production management
system relying on technical verification of both facility
and human operations. Through its quality and safety
management system, Daiichi Sankyo has established its
own high standards with world-class validation processes
and has developed a highly reliable global supply system.
Stable manufacturing and supply
Pharmaceuticals contribute to the health of people all over
the world, and Daiichi Sankyo has established internal
systems to ensure a high level of safety management. It
conducts ongoing training to make sure that each employee
is aware of and adheres to the Company’s safety policies.
Daiichi Sankyo exhaustively compiles safety management
information ( such as information on side effects ) from
around the world and provides accurate information on
appropriate usage to medical professionals.
Safety management system
Securing high quality and reliability; delivering a stable supply of world-class products
Ou
r Messag
eB
usiness S
trategyR
&D
Marketing
CS
RH
istory
Regio
nal Activities
■P07-08
The antihypertensive agent olmesartan medoxomil is an
angiotensin II receptor blocker (ARB), which has a strong
and continuous antihypertensive action in comparison to
other drugs in its class and is expected to achieve superior
results in preventing end-organ damage. As a best-in-class
ARB, it was launched in the United States and Europe in
2002 and in Japan in 2004 (U.S. brand name, Benicar®;
Japanese and European brand name, Olmetec®). In recent
years, a large amount of data using Japanese subjects has
also been compiled. The praise garnered by this drug’s
strong antihypertensive action and high degree of
safety has been reflected in its sales around the world.
Olmesartan
Japan Company is committed to maximizing the Group’s
business performance in Japan. It consolidates functions
focused on our Japanese businesses, which include
innovative and established pharmaceuticals, and vaccines.
Japan CompanyOur European subsidiary, Daiichi Sankyo Europe, has
branches in 12 European countries—Great Britain,
Germany, France, Austria, Belgium, Switzerland, Spain,
Italy, Holland, Portugal, Turkey and Ireland—through which
it conducts business operations in the region.
Daiichi Sankyo Europe GmbH
ASCA Company was established to successfully develop
strategies for regions outside Japan, the United States
and Europe, and to promote medium- and long- term
growth in these rapidly growing markets.
ASCA Company
Ranbaxy is India’s largest pharmaceutical company
and one of the world’s top ten generic manufacturers.
Daiichi Sankyo acquired a majority share in Ranbaxy
in 2008.
Ranbaxy Laboratories Ltd.
Daiichi Sankyo Healthcare develops, manufactures and sells
non-prescription medications in Japan. The company also
offers non-medical goods, cosmetics and food products.
Daiichi Sankyo Healthcare Co., Ltd.
Our U.S. subsidiary, Daiichi Sankyo, Inc., currently markets
therapies in hypertension, dyslipidemia, diabetes, acute
coronary syndrome, and metastatic melanoma.
Daiichi Sankyo, Inc.
Luitpold Pharmaceuticals develops and markets drugs
and medical devices for healthcare professionals,
clinics and hospitals across the United States and Canada.
Luitpold Pharmaceuticals, Inc.
Developed solely by Daiichi Sankyo, edoxaban is an oral
anticoagulant that directly inhibits factor Xa, which plays an
important role in the coagulation process ( through which
blood clots ). In 2011, we launched edoxaban as Lixiana®
in Japan to prevent venous thromboembolism (VTE ) in
patients undergoing total knee replacement surgery, total
hip replacement surgery, and hip fracture surgery. It was
the f irst available factor Xa inhibitor in that countr y.
Global Phase 3 studies are currently underway for
thromboembolism associated with atrial fibrillation ( irregular
heart rate) and VTE in patients with deep vein thrombosis
(DVT) or pulmonary embolism (PE). This research includes
HOKUSAI-VTE, the largest single Phase 3 study for the
treatment and prevention of recurrences of VTE in patients
who have had an acute symptomatic DVT, PE, or both.
Currently, preparations are being made to submit an
application for the approval of this drug.
Edoxaban
Daiichi Sankyo has been developing denosumab since 2007,
when it licensed the rights from Amgen to manufacture and
market this antibody in Japan. Denosumab was developed
to treat and prevent various bone disorders including
osteoporosis and bone metastases ( the spread of cancer to
the bones). It is the world’s first human monoclonal antibody
to target RANK ligand, a protein that plays a key role in
bone breakdown. In Japan, Daiichi Sankyo received
approval to manufacture and market denosumab as
RANMARK® for the treatment of bone complications
stemming from multiple myeloma and bone metastases
from solid tumors in January 2012, and approval for the
treatment o f osteoporosis in March 2013, and the
Company began marketing it under the brand name,
Pralia®. Daiichi Sankyo is currently participating in the
global Phase 3 study of adjuvant treatment for women with
early-stage breast cancer, and is conducting Phase 2
studies on Japanese patients with rheumatoid arthritis and
giant cell tumor of the bone.
DenosumabDaiichi Sankyo discovered prasugrel with our Japanese
research partner, Ube Industries and developed it in
collaboration with Eli Lilly and Company. Prasugrel is an oral
antiplatelet agent that prevents blood clots. In 2009, we
launched it as Effient® in the United States and as Efient®
in Europe to prevent atherothrombotic events (causing
inflammation of the arteries) in patients with acute coronary
syndrome undergoing percutaneous coronary intervention
( PCI ). To date, prasugrel has been approved in more than
70 countries around the world. In Japan, Daiichi Sankyo
and Ube Industries, Ltd. are jointly developing the drug. In
June, 2013, we submitted an application for its manufacture
and sale as a treatment for ischemic heart disease in
patients undergoing PCI. In addition, Phase 3 clinical
trials are being conducted on patients with ischemic
cerebrovascular disease.
Signature products created by original R&DTranslating years of knowledge and technology into outstanding products
Business UnitsTo grow in this rapidly changing business environment, Daiichi Sankyo reinforces strategy development and implementation through a global management structure.
Prasugrel
Our business units include five corporate entities in the regions where we operate, as well as two business organizations - Japan Company and ASCA Company.
Ou
r Messag
eB
usiness S
trategyR
&D
Marketing
CS
RH
istory
Regio
nal Activities
■P09-10
Increasing Synergy with Japanese Group CompaniesDaiichi Sankyo fuses the technological expertise of 10 group companies within Japan that cover fields such as innovative pharmaceuticals, OTC pharmaceuticals, vaccines, and generic pharmaceuticals, to create synergy throughout the entire value chain and deliver further value to its customers.
Daiichi Sankyo Espha Co., Ltd.Based on the Daiichi Sankyo Group’s corporate philosophy
of “supplying pharmaceuticals that meet diverse medical
needs , ” Daiichi Sankyo Espha operates business
focusing on generic pharmaceuticals, for which there is
increased demand.
The company strives to deliver products that customers can
feel safe in using, not only in terms of quality, information,
and stable supply—the areas that are most important
to pharmaceutical customers—but also in terms of
af fordability, which is expanded through the availability
of generic quality pharmaceuticals.
www.daiichisankyo-ep.co.jp
Daiichi Sankyo Healthcare Co., Ltd.In response to the growing interest in self-medication,
Daiichi Sankyo Healthcare works toward realizing “Total
Healthcare” through the manufacture and sales of
Rx-to-OTC switch drugs and other OTC pharmaceuticals,
as well as functional skincare and food products.
www.daiichisankyo-hc.co.jp
Daiichi Sankyo Propharma Co., Ltd.As the major global manufacturing base for pharmaceutical
products developed by Daiichi Sankyo, Daiichi Sankyo
Propharma strives to maintain a stable supply of high-
quality pharmaceuticals. The company also contributes to
the development of new products by manufacturing
investigational agents that are used in clinical trials.
www.daiichisankyo-pp.co.jp
Daiichi Sankyo ChemicalPharma Co., Ltd.Daiichi Sankyo Chemical Pharma is a pharmaceutical
manufacturer that supplies active pharmaceutical ingredients
and intermediates. Using its expertise in the factory
manufacturing process, the company efficiently achieves
fast development, stable supply, high quality and low cost,
and thus delivers its products faster, more cheaply and in a
more stable manner.
www.daiichisankyo-cp.co.jp
Daiichi Sankyo Logistics Co., Ltd.Daiichi Sankyo Logistics stores and ships pharmaceuticals
on a subcontract basis to fulfill a role in Daiichi Sankyo’s
supply chain by maintaining high distribution quality and
ensuring a stable supply of goods.
Asubio Pharma Co., Ltd.Asubio Pharma is a drug discovery venture that creates and
disseminates innovative drug discovery concepts and
platforms to aid in the discovery of new drugs to unmet
medical needs. Asubio’s drug discovery research specializes
in core drug discovery functions (basic research to early-
phase clinical development ).
www.asubio.co.jp
Daiichi Sankyo RD Novare Co., Ltd. Daiichi Sankyo RD Novare is comprised of three units: a
drug discovery unit with an integrated initial drug discovery
function, an analysis center that provides a comprehensive
range of analytical services, and a clinical research
department that per forms high-quality clinical trial
monitoring and related tasks. The company thus plays a
critical role in the creation of innovative pharmaceuticals by
providing pharmaceutical R&D platforms.
www.daiichisankyo-rdn.co.jp
Daiichi Sankyo Business Associe Co., Ltd. Daiichi Sankyo Business Associe provides core general
business support services (HR, accounting, clerical tasks,
purchasing ) for all Daiichi Sankyo Group companies on
a subcontract basis. The company also serves as an
insurance and real estate agency. By offering superior
expertise to improve both operational quality and efficiency,
the company ensures a high degree of custome rsatisfaction.
Daiichi Sankyo Happiness Co., Ltd. Daiichi Sankyo Happiness is a special company established
in accordance with the Employment Promotion Act for
Persons with Disabilities in order to promote the hiring of
disabled persons by the Daiichi Sankyo Group. The
company provides a variety of services to the group, such
as the creation of medical representative sales promotion
tools, factory and laboratory uniform cleaning, laboratory
equipment cleaning, and mail services within the Group.
Kitasato Daiichi Sankyo Vaccine Co., Ltd.Launched as a joint venture between Daiichi Sankyo and
the Kitasato Institute, Kitasato Daiichi Sankyo Vaccine is a
core company that handles R&D and manufacturing for the
vaccine business. Working closely with the Kitasato Institute
and other research organizations and universities in Japan
and worldwide, the company per forms research and
development of new vaccines and manufactures and
markets high-quality, easy-to-administer vaccines.
www.daiichisankyo-kv.co.jp
Ou
r Messag
eB
usiness S
trategyR
&D
Marketing
CS
RH
istory
Regio
nal Activities
■P11-12
Daiichi Sankyo knows it must earn the trust of those who
use our products and services, as well as the governments,
NGOs and organizations with which we partner on our
social responsibility activities. To do so, we adhere to the
highest standards of corporate behavior, so that all of our
business operations comply with global norms and
standards. We also distribute comprehensive information
about our corporate activities, communicating honestly
with stakeholders in order to earn and maintain their trust.
A Company Worthy of Stakeholder Trust
Access to healthcare and medicine are important social
issues around the world. The Daiichi Sankyo Group strives
to offer a variety of solutions globally to advance society’s
access to quality healthcare.
It is estimated that more than one billion poor people
throughout the world suffer from AIDS, malaria, tuberculosis
and neglected tropical diseases. Additionally, there are
many others suffering from “orphan” diseases, where the
relatively small number of patients and high costs of R&D
result in limited medical progress despite the high need for
treatment for these intractable diseases.
We are engaging the talent and resources of the Daiichi
Sankyo Group in order to respond to unmet medical needs
throughout the world. This not only includes a focus on
treatments for wide-spread illness, but those considered to
be “orphan” diseases, as well.
In developing countries, access to medical services is
limited by economic and social conditions and poor
physical infrastructure, among other reasons. As a member
of the health and medical industry, the Daiichi Sankyo
Group contributes to solving these social issues in
cooperation with NGOs, national governments, and
local communities.
With the increasing globalization of business, the
international influence of corporate activities on the
environment and society is growing. Daiichi Sankyo strives
to contribute to the development of a sustainable society.
We conduct our corporate activities in accord with the laws
and regulations in each region while respecting international
norms and protecting the environments in which we operate.
Social Responsibility at the Daiichi Sankyo Group
The Daiichi Sankyo Group integrates corporate social responsibility into its business activities as part of its mission to contribute to the enrichment of quality of life around the world.
Corporate Social Responsibility
In 2011, as part of efforts to improve medical access in
emerging nations, the Daiichi Sankyo Group began
providing mobile medical services in rural areas of India,
Cameroon and Tanzania through cooperation with NGOs,
local governments and regional companies. Over the
five-year period ending in 2015, we expect to have provided
mobile medical services to approximately 300,000 people
who, otherwise, would have had more limited or no access
at all to modern healthcare services. In these activities, we
are leveraging the expertise and resources of Ranbaxy’s
mobile healthcare field clinics in India, and we are focusing
on projects that bring together the specialized knowledge
and resources of NGOs, local governments, and local
communities. This makes our activities a social
contribution unique to Daiichi Sankyo, and much more
than a mere donation.
Since its inception, our mobile medical service has provided
care to approximately 90,000 people in India, Cameroon,
and Tanzania. Because prevention of disease is always
more desirable than treatment, we have been carrying out
a variety of activities for promoting the importance of
parental care and the role good hygiene plays in health.
Among the successful programs being offered are health
checkups for expectant and nursing mothers and
vaccinations for infants.
We aim to enrich these activities in the future by expanding
cooperation across borders and organizations in order to
reduce infant death rates, improve the health of expectant
and nursing mothers, and prevent the spread of HIV/AIDS,
malaria, and other diseases.
Mobile Healthcare Field Clinics
Social Contribution Activities to Improve Medical Access
Contributions to Reducing Child Mortality and Improving Maternal Health
Ou
r Messag
eB
usiness S
trategyR
&D
Marketing
CS
RH
istory
Regio
nal Activities
■P13-14
Established in 2005 through the merger of Sankyo and Daiichi Pharmaceutical, Daiichi Sankyo has a rich history spanning more than 100 years. Below, we introduce our milestones, including those of Sankyo and Daiichi Pharmaceutical since the beginning.
2005Established by joint holding company of Sankyo Co., Ltd. and Daiichi Pharmaceutical Co., Ltd.
2006Began operations of Daiichi Sankyo Healthcare Co.,Ltd.; Daiichi Sankyo, Inc.; and Daiichi Sankyo Europe GmbH
2007Began operations on April 1, 2007as the newDaiichi Sankyo Group
2008Acquired U3 Pharma AG of Germany and became a majority stakeholder in Ranbaxy Laboratories Limited of India.
2009Launched Prasugrel, an antiplatelet agent and global product,in Germany (as Efient ®) and the United States (as Effient®)
History of Daiichi Sankyo Co., Ltd.
History of Sankyo Co., Ltd.1899Founded as Sankyo Shoten through a joint investment by businessmen Matasaku Shiobara, Shotaro Nishimura
and Genjiro Fukui 1910Dr. Umetaro Suzuki, a future Sankyo scientific adviser, made the world's first discovery of vitamin B11 ( Oryzanin®) in rice bran and established a foundation for the theory of vitamins
1913Changed company name from Sankyo Shoten to Sankyo Co., Ltd. Appointed Dr. Jokichi Takamine as first president
1949Listed on Tokyo Stock Exchange
1951Launched LULU® cold medicine
1977Launched Krestin®, an anticancer drug
1986Launched the anti-inflammatory, analgesic drug, Loxonin® in Japan
1989Globally launched Mevalotin®, a groundbreaking HMG-CoA reductase inhibitor ( hyperlipidemic drug )
1992Awarded the Ohkochi Memorial Grand Production Prize for Mevalotin®
1994Completed construction of head office building in Nihonbashi, Tokyo, Japan
1998Became the first pharmaceutical company in Japan to receive ISO 14001 environmental certification for its Onahama and Odawara plants
Daiichi Sankyo’s History
2010Launched Rezaltas®, a high-affinity ARB/ long-acting calcium antagonist compound, and Inavir ®, an anti-influenza virus agent
Began operations of Daiichi Sankyo Espha Co., Ltd.
2011Acquired Plexxikon Inc. of the United States
Began operations of Kitasato Daiichi Sankyo Vaccine Co., Ltd.
Launched Memary® for treatment of Alzheimer's disease, Lixiana®, an oral FXa inhibitor, and Nexium®, a proton pump inhibitor
Consolidated Daiichi Sankyo head office and the head offices of Japan Group companies in the Nihonbashi area of Tokyo, Japan
2012Opened Daiichi Sankyo Kusuri Museum in Tokyo
Launched RANMARK®, an antibody that targets RANK ligand, and TENELIA ®, a therapeutic agent for type 2 diabetes
Began operations of Japan Vaccine Co., Ltd., a joint venture with GlaxoSmithKline K.K.
2013Launched Pralia®, a treatment for osteoporosis
History of Daiichi Pharmaceutical Co., Ltd.1915Founded as Arsemin Shokai by Dr. Katsuzaemon Keimatsu and five others
1949Listed on Tokyo Stock Exchange
1965Completed construction of former head office building inNihonbashi, Tokyo, Japan
Launched the anti-fibrinolytic Transamin®
1966Launched Patex®, the first flexible medicated bandage
1993Launched Cravit®, a broad-spectrum oral antibacterial agent
1973Launched Karoyan®, a hair restoration agent
1985Launched Tarivid® a broad-spectrum oral antibacterial agent, in Japan and the former West Germany
1918Changed company name from Arsemin Shokai to Daiichi Pharmaceutical Co., Ltd.
Appointed Seinosuke Shibata as first president
1937Launched Therapol®, the first sulfa drug produced in Japan
Ou
r Messag
eB
usiness S
trategyR
&D
Marketing
CS
RH
istory
Regio
nal Activities
■P15-16
■P17-18
Corporate InformationCompany Name: Daiichi Sankyo Company, LimitedBusiness: Research and development, manufacturing, import, sales and marketing of pharmaceutical productsHeadquarters: 3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, 103-8426, JapanTelephone: +81-3-6225-1111Established: September 28, 2005Paid-in Capital: ¥50,000 millionEmployees: Approximately 32,000
Corporate Profile
Group Companies in JapanDaiichi Sankyo Espha Co., Ltd.Daiichi Sankyo Healthcare Co., Ltd.Daiichi Sankyo Propharma Co., Ltd.Daiichi Sankyo Chemical Pharma Co., Ltd.Daiichi Sankyo Logistics Co., Ltd.Asubio Pharma Co., Ltd. Daiichi Sankyo RD Novare Co., Ltd.Daiichi Sankyo Business Associe Co., Ltd.Daiichi Sankyo Happiness Co., Ltd. Kitasato Daiichi Sankyo Vaccine Co., Ltd.
Worldwide Group CompaniesDaiichi Sankyo, Inc. (United States)Luitpold Pharmaceuticals, Inc. ( United States )Plexxikon Inc. (United States)Daiichi Sankyo Europe GmbH (Germany)Daiichi Sankyo France SASDaiichi Sankyo Deutschland GmbHDaiichi Sankyo Italia S.p.A.Daiichi Sankyo España, S.A.Daiichi Sankyo UK Ltd. (England)Daiichi Sankyo ( Schweiz ) AGDaiichi Sankyo Portugal, Lda.Daiichi Sankyo Austria GmbHDaiichi Sankyo Belgium N.V.-S.A.Daiichi Sankyo Nederland B.V.Daiichi Sankyo Ilaç Ticaret Ltd. ŞŞti.Daiichi Sankyo Ireland Limited.Daiichi Sankyo Altkirch Sarl (France)U3 Pharma GmbH (Germany )Daiichi Sankyo Development Ltd. ( England )Daiichi Sankyo (China ) Holdings Co., Ltd.Daiichi Sankyo Pharmaceutical (Beijing ) Co., Ltd. ( China)Daiichi Sankyo Pharmaceutical (Shanghai ) Co., Ltd. (China)Daiichi Sankyo Taiwan Ltd.Daiichi Sankyo Korea Co., Ltd.Daiichi Sankyo (Thailand) Ltd.Daiichi Sankyo Hong Kong LimitedDaiichi Sankyo Mexico, S.A. de C.V.Daiichi Sankyo Brasil Farmacêutica LTDA.Daiichi Sankyo Venezuela S.A.Daiichi Sankyo India Pharma Private Ltd. Ranbaxy Laboratories Ltd. Group (India)
Directors,Officers and AuditorsRepresentative Director, ChairmanTakashi Shoda
Representative Director, President and CEOJoji Nakayama
Members of the Board, Members of the Audit and Supervisory Board, and Corporate OfficersTakeshi Ogita Kazunori HirokawaYuki SatoManabu Sakai
Members of the Board (Outside ) Hiroshi Hirabayashi Kunio Ishihara Ichiro KanazawaSeiji Sugiyama
Members of the Audit and Supervisory BoardKazuo KoikeTakashi Chiba
Members of the Audit and Supervisory Board (Outside )Akio YamadaShigeaki Ishikawa
Senior Executive OfficersGlenn GormleyRyouichi Kibushi
Executive OfficersShuji HandaTomoo Yokoi
Corporate OfficersSunao ManabeNoriaki IshidaKatsuaki MiyoshiSatoshi KunitadaShinichi TeranoToshiaki SaiKatsumi FujimotoRyoji Nagasaka Toshiaki TojoJunichi KogaKoichi AkahaneKenji InoueKazuo SatoNorimasa Kamura
( as of October 2013 )
Japanese OfficesBranch OfficesSapporoTohokuTokyoChibaSaitamaYokohamaKita-KantoKoushinetsuToukaiKyotoHokurikuOsakaKobeChugokuShikokuKyushu
Research LaboratoriesShinagawa R&D CenterKasai R&D Center
Factories ( Daiichi Sankyo Propharma Co., Ltd.)Akita PlantOnahama PlantTatebayashi PlantHiratsuka PlantTakatsuki Plant
Factories (Daiichi Sankyo Chemical Pharma Co., Ltd.)Hiratsuka PlantOdawara Plant
Distribution Center (Daiichi Sankyo Logistics Co., Ltd. )Tokyo Distribution Center
Facts & Figures
1,000
( billions of yen )
750
500
250
0FY2008 FY2009 FY2010 FY2011 FY2012
1Q 2Q 3Q 4Q
Net sales
YTD FY2008 FY2009 FY2010 FY2011 FY2012
1Q 203.7 227.1 256.4 231.7 242.6
2Q 406.3 470.6 498.9 456 484.2
3Q 627.6 725.7 748.1 696.4 745.6
4Q 842.1 952.1 967.4 938.7
Net sales by segment ( for the first six months of FY 2012)
Japan
North America
Daiichi Sankyo Group
Europe
Other regions
Ranbaxy Group
Ranbaxy Group185.4 billion yen( 19%)
Daiichi Sankyo Group812.4 billion yen( 81%)
FY2011 FY2012
600( billions of yen )
400
200
0FY2011
Daiichi Sankyo Group: JapanDaiichi Sankyo Group: Europe
Daiichi Sankyo Group: North AmericaDaiichi Sankyo Group: other regions
Ranbaxy Group
Net sales share by segment
FY2012
1,500
1,250
1,000
750
500
250
( billions of yen )
0
60
50
40
30
20
10
( %)
0
Domestic sales Overseas sales Percent of net sales
Overseas sales, percent of net sales
Overseas sales 358.6 373.3 482.3 489.7
Domestic sales 521.5 468.8 469.8 477.7
Percent of
net sales 41% 44% 51% 51%
FY2008 FY2009 FY2010 FY2011 FY2012
R&D expenses
Percent of net sales
250
( billions of yen )
200
150
100
50
0
R&D expenses
R&D expenses, percent of net sales
Percent of net sales
25
20
15
10
5
( %)
0
Financial Highlights ( as of May 2013 )
1Q 2Q 3Q 4Q
1Q
2Q
3Q
4Q
Japan
North America
Daiichi Sankyo Group
Europe
Other regions
Ranbaxy Group
997.9
FY2008 FY2009 FY2010 FY2011 FY2012
486.7
511.2
49%
FY2008 FY2009 FY2010 FY2011 FY2012
100.5
125
( billions of yen )
100
75
50
25
0FY2008 FY2009 FY2010 FY2011 FY2012
Operating income
YTD FY2008 FY2009 FY2010 FY2011 FY2012
40.0 26.8 61.1 43.5 32.5
61.6 50.9 90.1 62.2 57.1
98.1 90.1 120.6 91.9 93.5
88.9 95.5 122.1 98.2
528.6
182.3
997.9
812.4
60.6
40.9
185.4
NorthAmerica
Europe Japan
Otherregions
490.0
177.0
763.2
67.4
28.8
175.5
528.6
182.3
812.4
60.6
40.9
185.4
184.5 196.8 194.3 185.1
22% 21% 20% 20%
183.0
18%
FY2008 FY2009 FY2010 FY2011 FY2012
1Q 2Q 3Q 4Q
125
( billions of yen )
100
75
50
25
0FY2008 FY2009 FY2010 FY2011 FY2012
Ordinary income
YTD FY2008 FY2009 FY2010 FY2011 FY20121Q
2Q
3Q
4Q
40.9 7.2 70.1 44.8 40.8
59.6 52.3 92.6 66.3 49.9
93.2 90.6 130.6 86.4 95.7
55.2 103.1 131.8 76.2 99.1
1Q 2Q 3Q 4Q
100
( billions of yen )
0
-100
-200
-300
Net income
YTD1Q
2Q
3Q
4Q
FY2008 FY2009 FY2010 FY2011 FY2012
FY2008 FY2009 FY2010 FY2011 FY2012
25.1 6.4 33.1 25.3 20.4
34.0 18.7 52.2 37.0 24.4
297.8 39.2 79.7 17.5 51.5
215.5 41.9 70.1 10.4 66.6
■inserts